Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX04 vs Bevacizumab in First-line mCRC
NCT03511963Phase 3Completed
- Sponsor
- Henlius
- Start
- Apr 2018
- Primary completion
- Apr 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of HLX04-O in metastatic colorectal cancer (mCRC), sponsored by Henlius. Started Apr 2018; status: completed.
02
Drugs
HLX04-O
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03511963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03511963.